S ince its introduction in the 1980s, antiretroviral therapy (ART) for HIV infection has reached millions of people worldwide. The Joint United
Nations Programme on HIV/AIDS (UNAIDS) estimates that 2 million HIV-positive people in low-and middle-income countries were on ART by the end of 2006, a 54% increase over the previous year. 1 Great disparities in access to ART persist between underserved regions, ranging from 6% of patients who are clinically eligible for treatment in North Africa and the Middle East to 72% in Latin America and the Caribbean. 1 Yet access to these life-saving drugs continues to improve in low-and middle-income countries, where so few HIV-positive patients were on ART only a decade ago.
Despite the ever-growing availability of antiretroviral drugs, little is known about differences in knowledge, attitudes, behaviors, hopes, and fears of people living with HIV and AIDS in the economically disparate regions affected by the epidemic. A PubMed search of the terms attitude, patients, and HIV found fewer than 50 articles published in the past 10 years, all of them limited to single centers or countries, and all addressing limited questions such as knowledge, attitudes, and behaviors in psychiatric outpatients 2 ; decisions on when to start ART 3 ; opinions on antiretroviral drug allocation policies 4 ; and knowledge, beliefs, and behaviors in injection drug users. 5 Better understanding of differing opinions and behaviors among HIV-positive people from different regions will do more than satisfy curiosity about these issues. It may also (1) help clinicians and policymakers understand the needs and motivations of diverse HIV-positive populations; (2) point out shortcomings in patient education; (3) raise patient, public, and professional awareness of perceptions about HIV infection and care; and (4) uncover questions for more focused research.
For these reasons, the International Association of Physicians in AIDS Care (IAPAC) conducted a cross-sectional, multinational, comparative, treatmentawareness survey in 6 regions with 3 principal goals: 
Methods
The International Association of Physicians in AIDS Care (IAPAC) worked with Ipsos Insight Health, an independent marketing research firm, to survey HIVpositive adults from 6 regions in a convenience sample: North America (United States), Latin America (Argentina, Brazil, and Mexico), the Caribbean (Dominican Republic, Jamaica, and Puerto Rico), Europe (France, Germany, Italy, Russia, and Spain), Asia/Pacific (Korea, Malaysia, and New Zealand), and Africa (South Africa). Japan, Singapore, and the United Kingdom were also among the The AIDS Treatment for Life International Survey (ATLIS) survey countries; however, not enough respondents could be recruited from these 3 countries in time for this analysis. From March 2008 through May 2008, we attempted to survey at least 200 people to obtain relatively robust analytic bases in each country. In countries where recruitment was especially difficult, we revised the recruitment goal to 100 patients. At a 95% confidence level, in countries in which n = 200, the error margin is approximately 6.6%; in countries in which n = 100, the error margin is approximately 9.5%. The goal of this research was to analyze differences in knowledge and perception among people living with HIV and AIDS in different regions of the world. The analysis of the survey results was exploratory in nature, in that we did not test predefined hypotheses. Rather, we have summarized the vast amount of data collected and noted where significant (pairwise) differences due to, for example, region, gender, or treatment status were found. Significance was determined using appropriate tests of independence (z test for proportions and t test for means). Differences were deemed statistically significant if the P value for the associated test was less than .05. The analysis was simplistic in that it did not correct for multiple comparisons or take into account differences that could be attributed to interview type or differences in wording and question choices that were country dependent on some of the questions.
Field workers aimed to recruit participants with ART experience and others who had never taken antiretroviral drugs. Potential participants were contacted through a combination of online panels, purchased online and offline samples, and alternative fieldwork providers. The 3 recruitment and fielding strategies included (1) Internet (respondents proactively accessed and completed survey via an online portal); (2) telephone/Internet combination (respondents recruited via random telephone dialing and provided with online survey link); and (3) Webassisted telephone or face-to-face interviews (respondents recruited via phone or in person and surveyed via phone or in person, with the interviewer completing their survey online).
The mode of recruiting was determined based on the most effective and appropriate approach for recruiting HIV-positive patients in each country surveyed. For example, recruitment strategies differed in the United States, where there is ready access to large general-population consumer panels, and in Singapore, where most HIV-positive patients are treated in one large hospital group, the HIV population is small, and there is significant social stigma attached to HIV infection. Depending on the form of recruitment, the percentage of respondents ultimately willing to participate in the survey varied. For instance, in countries where recruitment targeted hospitals, support groups, and physicians, the total number of individuals contacted was much lower because of the concentration of qualified respondents.
In the United States, recruitment relied on general consumer online panels, through which 5800 potential participants were contacted. Of those, 2200 qualified (37.9%) and 210 (9.5% of those qualified) ultimately completed the survey.
In many countries, HIV-positive patients were not readily accessible through standard channels of recruitment. Hence, alternative recruitment modalities were implemented to reach potential participants. In South Africa and Malaysia, respondents were recruited through clinics. Physicians or HIV clinic coordinators referred potential respondents to complete the survey. In South Africa, 233 individuals were contacted and 200 respondents (85.8%) ultimately qualified for and completed the survey. In Malaysia, 110 individuals were contacted and 100 (90.9%) qualified for and completed the survey.
In both Mexico and the Caribbean, recruitment was conducted through health care centers, HIV and AIDS associations, and referrals. Because we relied partly on referrals in Caribbean countries, the number of potential participants ultimately contacted cannot be quantified; however, through all methods of recruitment, 205 potential participants were formally invited to complete the survey in Mexico and 5 (2.4%) refused participation. In the Caribbean, 213 participants were formally invited to complete the survey and 13 (6.1%) refused participation.
In Spain, Russia, and New Zealand, respondents were contacted through HIV support groups, HIV treatment centers, and HIV and AIDS associations. In Spain, 85 HIV and AIDS associations were contacted, 18 associations ultimately participated in the study, and 202 interviews were carried out. In Russia, 350 potential participants were contacted through HIV treatment centers and 200 respondents (57.1%) ultimately qualified for and completed the survey. Through support groups in New Zealand, 207 potential participants were contacted and 106 respondents (51.2%) qualified for and completed the survey.
The number of potential participants contacted in Germany, France, and Korea cannot be quantified because recruitment took place through referrals from individual physicians. Consequently, the number of initial contacts was difficult to determine because one contact may have led to another. However, 205 respondents in Germany ultimately qualified for and completed the survey. In France, 224 potential participants ultimately qualified for the survey and 202 individuals (90.2%) completed the survey. In Korea, 130 ultimately qualified for and completed the survey.
In Italy, Argentina, and Brazil, potential participants were contacted through a combination of online panels and purchased online and offline samples. In Italy, 500 individuals were contacted, 450 respondents qualified, and 200 completed the survey (44.4% of those qualified). In Argentina, 580 potential participants were contacted, of which 534 qualified and 204 (38.2% of those qualified) ultimately completed the survey. In Brazil, 655 respondents were contacted, 576 qualified, and 203 (35.2% of those qualified) completed the survey.
These recruitment methods do not ensure that the surveyed participants represent all individuals recruited or the HIV-infected population of an entire country.
We translated the questionnaire into local languages and tailored each questionnaire to include socially acceptable language. The survey took approximately 20 minutes to complete. Most questions were asked in a multiple-choice or yes/no format.
We conducted the entire recruitment and fielding process in a confidential manner. No personal identifying details were collected or attributed to respondents. All respondents signed confidentiality/ nondisclosure agreements before beginning the survey to ensure any information they shared would be kept confidential in accordance with local laws.
Role of the Funding Source
Merck & Co, Inc, was consulted on the study design but played no role in data collection, data analysis, data interpretation, or writing of this report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
The total number of HIV-positive individuals who were invited to complete the survey is unquantifiable due to the confidential nature of the field process; however, a total of 2555 did so ( Table 1) . Because of slow recruitment in Japan, Singapore, and the United Kingdom, those countries are not included in this analysis. We stopped recruitment at 130 people in Korea and at 100 in Malaysia and New Zealand. We met recruitment goals in all others countries.
Demographic Characteristics
Approximately two thirds of participants in this crosssectional survey were men, except in South Africa, where 62.5% of participants were women; in the Caribbean, where 61.5% were women; and in Brazil, which included equivalent proportions of men and women (Table 1 ). More than 9 in 10 respondents in New Zealand (96%) and the United States (90.5%) were men. Mean ages stood in the late 30s or early 40s in all countries except Russia (27.3 years). The oldest participants were from France (mean 44.7 years), New Zealand (45), and the United States (44.2 years).
Proportions of heterosexuals and men who have sex with men (MSM) plus bisexuals were statistically equivalent in France and in Germany, whereas heterosexuals predominated in Italy, Spain, the Caribbean, Argentina, Brazil, South Africa, Russia, and Malaysia, and MSM and bisexuals predominated in the United States, Mexico, New Zealand, and Korea (Table 1) . United States respondents were significantly less likely to be heterosexual than respondents in other regions (P < .05). Married people represented minorities of every study population, ranging from 5.4% in Spain to 32% in Malaysia. The highest proportions of singles not in long-term relationships came from Korea (59.2%), New Zealand (51.5%), and Russia (51%), whereas singles in longterm relationships made up pluralities in the United States (43.8%) and South Africa (42%).
Educational levels varied greatly from country to country. United States respondents were the most highly educated, with all but 1% graduating high school (Table 1 ). In contrast, 13.5% to 59.5% of respondents in European countries had less than a high school-equivalent certificate. Among Latin American countries, Argentina had the best-educated respondents, although 45% or more respondents in Brazil, Mexico, and the Caribbean had less than a high school certificate. Proportions with less than a high school-equivalent certificate were 20.8% in Korea, 38% in Malaysia, 39.6% in New Zealand, and 57.5% in South Africa.
Employment rates also differed greatly from country to country. The United States (56.2%) and Malaysia (51%) had by far the highest proportion of full-time-employed participants ( 
HIV and General Health Status
Half of all survey respondents reported good overall physical health, with significantly more US and Latin American respondents claiming good health than those in other regions (P < .05). European and US respondents who are not on ART were significantly more likely to report good health than those not on treatment in those countries (P < .05). United States respondents not taking antiretroviral drugs were significantly more likely to report good health than those in other regions not taking antiretroviral drugs (P < .05). (Data on general health status are available at www.iapac.org.)
Overall self-perceived good health was highest in New Zealand (65.3% of respondents), Argentina (63.7%), Brazil (63.5%), the Caribbean (63%), and the United States (61.9%), and lowest in Italy (26.5%), Korea (33.1%), and Germany (44.4%). The highest proportions of respondents reporting poor overall health lived in Italy (25%) and Spain (16.8%). Despite challenged health care systems in Russia, the Caribbean, and South Africa, few respondents in those countries reported poor overall health (6%, 7%, and 13%, respectively). The most common comorbidities were depression, high total cholesterol, and high blood pressure. But self-reported prevalence of these conditions varied considerably from region to region. For example, depression rates stood at 59% in the United States and 56.4% in New Zealand, while ranging from 35.1% to 58.4% in Western Europe and from 17.5% to 46.1% in Latin America, but measuring only 21.5% in Russia, 18% in South Africa, 16.9% in Korea, and 15% in Malaysia. United States respondents reported the highest prevalence of high blood pressure (35.2% of respondents), compared with 28.7% in New Zealand, ranges of 16.5% to 24% in Western Europe, 9.5% to 17.5% in Latin America, and 10% to 15% in other countries. These higher rates of depression and hypertension in the United States contrast with the generally better perception of overall health by US respondents than by respondents from other countries.
More than half of all survey respondents had HIV infection for 1 to 6 years. French, Spanish, and US respondents had been infected longest (mean 13.2, 11.8, and 11.4 years), whereas South African, Korean, Russian, and Mexican patients (mean 4.4, 4.8, 4.9, and 4.9 years) had HIV for the shortest periods. Differing availability of HIV testing services and promotion of HIV testing probably explain some of the difference in HIV testing rates. Overall, respondents taking medications for HIV or AIDS have been infected with HIV significantly longer than those who were untreated (P < .05).
Most respondents discovered their HIV infection in one of two ways-while in the hospital for another reason or after actively seeking HIV testing. United States respondents were significantly more likely than others to actively seek HIV testing (P < .05). Asian respondents were more likely to discover their HIV status while in the hospital for another reason than were all other participants except South Africans (P < .05).
Overall, nearly three quarters of respondents were taking prescription medications for HIV or AIDS when they completed the survey (from 62.5% in Russia to 87.5% in France). Current treatment rates did not differ substantially between men (73.8%) and women (70.4%). Proportions who ever took HIV or AIDS medications ranged from 68% in Russia to 94% in France. Among respondents who stopped taking antiretroviral drugs, the reasons most frequently cited for stopping were side effects, physician advice, and difficulty in keeping up with doses. Reasons differed slightly from region to region, with side effects and physician advice predominating in Western Europe (with the exception of Spain where side effects and the development of antiretroviral drug resistance predominated), Latin America, the United States, South Africa, and New Zealand. In Russia, difficulty in keeping up with doses was the principal reason for stopping (80%), followed by side effects (70%), whereas in Malaysia, fear of HIV status disclosure was the single most common reason (66.7%). After side effects, the second most common reason for stopping in South Africa was belief that the drugs were not working (25%).
One in 5 respondents have never taken prescription medication for HIV or AIDS. The most frequent reason for never being treated is a physician told them they are not eligible for treatment (30.4%), followed by the belief that they are not in danger of getting ill from HIV or AIDS (13.3%) and that they do not believe treatment will help them (10%). Asia/Pacific and European respondents were significantly more likely than respondents from the United States, Latin America, or South Africa to believe they are not in danger of getting ill from HIV or AIDS (P < .05), and Asia/Pacific respondents are significantly more likely to hold that belief than any other regional groups (P < .01, versus Europe, P < .05, versus all other regions).
Current Regimens, Adherence, Tolerability
Whereas 69.8% of respondents were taking HIV or AIDS drugs for at least 1 year, 31.2% were taking their current antiretroviral regimen for 1 to 2 years. Time on current regimen was longest in countries where these drugs have been widely available longest-Spain (52.3% for more than 2 years), France (49.2%), the United States (46.3%), and New Zealand (41.1%) ( Table 2 ). In contrast, only 8% of Russian respondents have been treated for more than 2 years, although treatment duration rates are high in Malaysia (52% more than 2 years) and Brazil (51.8%) and moderately high in Argentina (39.6%), Korea (39.6%), South Africa (34.3%), Mexico (34%), and the Caribbean (34%). Self-reported adherence to ART was high in most countries, with approximately 75% or more of respondents claiming they never or rarely missed doses in all Western European countries, as well as in all Latin American countries except Brazil, and in South Africa, Russia, Malaysia, and New Zealand (Table 2) . Countries with the highest proportions reporting that they sometimes, frequently, or always missed doses were Korea (35.2%) and Brazil (33.4%). Respondents in South Africa and Latin America were significantly more likely than others to report never missing a dose (P < .05).
Large majorities of respondents in almost every country reported satisfaction with the tolerability of their antiretroviral regimen ( Table 2 ). Three exceptions were Italy, where only 43.7% rated their regimen tolerable; Korea, where 55% deemed their regimen tolerable; and Brazil, where 56.7% called their treatment tolerable. Opinions about drug tolerability varied by gender. In Latin America, male respondents were significantly more likely than female respondents to be extremely satisfied with the tolerability of their HIV medications (P < .10).
Results varied more from region to region when respondents were asked whether their treatment had a negative impact on quality of life ( Table 2 ). The highest rates of quality-of-life complaints came from Germany (58.4%) and Korea (57.1%). Majorities in all other countries said treatment did not hurt their quality of life.
Side Effects, Switching, and Resistance
More than half of all respondents worried that their medications will cause face or body shape changes (57%), gastrointestinal problems (54%), liver problems (54%), fatigue or anemia (54%), or joint/muscle pain or weakness (49%). But other side effect concerns were also common: sleep disorders (49%), cardiovascular complications (48.7%), kidney disease (45%), neuropathy (43%), and bone loss (39%). Latin American and US respondents voiced substantially more concern about potential side effects than others (P < .05), and South African respondents voiced substantially less concern (P < .05). Female respondents, especially in Latin America and Europe, worried more than men about bone loss and face or body changes. Male and female respondents in Brazil (61.7%) and Argentina (61%) were the most likely to say they are "very" concerned about body shape changes (Table 3 ). Nearly two thirds of Russian respondents (65.6%) claimed to be "very" concerned about possible liver toxicity.
Whereas 37% of respondents have never switched their antiretroviral regimen, 61.6% have changed antiretroviral drugs in their regimens at least once. South African respondents were significantly more likely to be taking their first regimen (P < .05), a result probably reflecting later introduction of ART in South Africa and more limited second-or third-line options. The highest proportions of respondents who switched drugs more than once came from France (70.3%), the United States (66.3%), and Spain (61%) ( Table 4) . Overall, female respondents were significantly less likely to change antiretroviral drugs than male respondents (P < .05), especially in Latin America, where more than half of women have not changed antiretroviral drugs.
The 3 most common reasons for changing drugs were side effects (39.4%), physician advice (23.2%), and resistance to antiretroviral drugs (18.7%). Male respondents in Latin America and Asia/Pacific countries were significantly more likely than female respondents to change antiretroviral drugs because of resistance. South African respondents were significantly less likely than others to change antiretroviral drugs because of resistance, a finding that may reflect lower rates of resistance testing in South Africa (P < .05). More than 20% of respondents reported ever having resistance in Argentina (35.3%), Spain (28.2%), Italy (28%), France (21.5%), New Zealand (20.8%), and the United States (20.5%) ( Table 4) . These results must be interpreted cautiously because many respondents said they did not know the definition of resistance.
Opinions on Current and Future Medications
More than 7 in 10 respondents said they wished they knew more about HIV disease and its treatment, but proportions of respondents feeling underinformed varied from region to region. Latin American respondents were significantly more likely than others to want to learn more about HIV disease and its treatment (P < .05), whereas US respondents were significantly less likely to want to learn more (P < .05). Whereas more than 60% of respondents in all Latin American regions wanted to learn more, only 12.4% in the United States felt the same need. (Data on current and future medications are available at www.iapac.org.) High interest in learning more about HIV disease was also expressed by respondents in Malaysia (86%), South Africa (70.5%), and Russia (67%).
High proportions of respondents in every region agreed that they would take their HIV medications over the long term to prevent health risks, with the highest proportions of affirmative responses coming from Malaysia (80%) and Mexico (71%) and the lowest proportions from Brazil (30.5%), Russia (36%), and Italy (38%).
Three quarters of respondents voiced optimism that current and imminent HIV medications will help them live a long life with HIV, though US and European respondents were significantly less likely to hold this opinion (P < .05). A country-by-country analysis indicates that the highest proportions of optimistic respondents live in Malaysia (85%), Mexico (75.5%), and the Caribbean (71%) and the lowest proportions live in Korea (27.7%), Italy (21.5%), and Russia (38.5%).
More than half of all respondents (57.9%) stated that the benefits of HIV and AIDS treatment outweigh potential side effects. European and South African respondents were significantly less likely than others to believe treatment benefits outweigh risks (P < .05). United States respondents were significantly more hopeful than others that ART will keep their HIV-RNA viral load as low as possible and CD4 cell count as high as possible (P < .05). Overall, male respondents were significantly more likely than female respondents to hope that treatment would keep their viral load low and prevent opportunistic infections (P < .05). Across all regions, only small minorities felt that the number of pills they take daily or the amount of time they spend taking pills affects their quality of life.
Easily the highest priority for future HIV and AIDS medications is help in living longer, outweighing desires for greater convenience, fewer side effects, lower cost, better access, or new mechanisms. (Data on priorities for future medications are available at www.iapac.org.) Priorities differed from country to country. European respondents were significantly more likely than others to hope new antiretroviral drugs will improve survival (P < .05), and Asia/Pacific respondents were significantly less likely to express that hope (P < .05). German and Spanish respondents emphasized fewer side effects, whereas US respondents wanted antiretroviral drugs they will not have to take for life.
Knowledge of HIV Disease and Antiretroviral Drugs
Three in 5 respondents understood that having an undetectable viral load means < 50 HIV RNA copies/mL in plasma. United States participants had a significantly greater understanding of this concept (P < .05), whereas South African (P < .05) respondents had a significantly lower understanding than respondents from all regions and Asia/Pacific respondents had a significantly lower understanding than US respondents (P < .05). Regardless of region, respondents taking antiretroviral drugs were significantly more likely to understand what an undetectable viral load means. Overall, 37% of respondents said they do not know how resistance to antiretroviral drugs develops. Respondents not taking antiretroviral drugs were significantly more likely than those being treated to concede they do not understand how resistance occurs (P < .05), and South African respondents were significantly less likely than others to understand resistance (P < .05).
In Western Europe, substantially fewer Italian respondents (34%) understood what an undetectable viral load means than did those in other Western European countries (66.8% to 81.5%) ( Table 5 ). In Latin America, 77.9% of Argentines understood the concept of undetectability, compared with about half of respondents in the Caribbean and Mexico and about one third in Brazil. Malaysian respondents had the lowest proportion of respondents who correctly described an undetectable viral load (22%), even though the Malaysian group did not differ substantially from others in the proportion taking antiretroviral drugs.
Among Western European and US respondents, those in the United States (13.3%) were least likely not to know their CD4 cell count, whereas those in Germany (43.6%) and Italy (37.5%) were most likely not to know their CD4 cell count (Table 5 ). Only 7.8% of Argentine respondents did not know their CD4 cell count, compared with 29% of Caribbean, 43% of Mexican, and 63.5% of Brazilian respondents. Small minorities of South African, Korean, Malaysian, and New Zealander respondents did not know their CD4 cell count, compared with 43% of Russian respondents.
Overall, survey respondents were most aware of protease inhibitors (26% awareness) as an antiretroviral drug class, followed by nucleoside reverse transcriptase inhibitors (22%), nonnucleoside reverse transcriptase inhibitors (19%), entry inhibitors (including enfuvirtide and CCR5 antagonists) (14%), and integrase inhibitors (14%). Significantly more respondents in the United States than in all other regions had higher awareness of all antiretroviral drug classes (P < .05).
Still, proportions of respondents very or somewhat aware of protease inhibitors exceeded 50% in only the United States (67.7%), compared with 12.0% in Mexico, 10.0% in the Caribbean, and 10.0% in Malaysia (Table 5 ). Fewer respondents in most countries were very or somewhat aware of entry inhibitors and integrase inhibitors than they were aware of protease inhibitors.
Concerns and Fears About HIV Status
More than half of all respondents expressed concern about others knowing their HIV status, with significantly more untreated people than treated people stating this concern (P < .05). Compared with respondents in other countries, South African respondents were significantly less concerned about others knowing their HIV status (P < .05), whereas Asia/Pacific respondents were more likely to express concern (P < .05). Rating serostatus concern as a mean score on a 1 to 5 scale with 1 being not at all concerned and 5 being very concerned showed that French respondents had the least concern among Western European and US respondents (mean 2.4). (Data on concerns about HIV status are available at www.iapac.org.) In Latin America, the Caribbean, and Mexico, respondents expressed less concern (means of 3.1 and 3.2) than did Brazilian (3.8) or Argentine (3.9) respondents.
Although higher proportions of respondents said it was more difficult to tell parents about their HIV status than to tell siblings, friends, and others, parents were the most likely group to be told. South African respondents proved significantly more likely than others to reveal their serostatus to family members, including parents, siblings, and children (P < .05). United States respondents were significantly more likely to tell spouses or significant others, sex partners, individuals in the community, and employers (P < .05). Latin American respondents were significantly more likely to disclose their serostatus to "everyone," including 26.5% of Argentine and 22.5% of Caribbean respondents. In contrast, only 10% of US respondents and 5% of South African respondents told everyone. Although a relatively high proportion of Russian respondents (15%) told "everyone," even more (21%) told "no one."
Among all respondents, women were significantly more likely than men to tell children they have HIV infection (P < .05), whereas men were significantly more likely to tell friends, employers, and individuals in the community (P < .05). Across all regions, male respondents were significantly more concerned than female respondents about losing their job or health insurance because they have HIV (P < .05).
Becoming too sick to care for oneself and dying were the greatest overall fears about being infected with HIV. But the category of greatest fears about being infected varied from country to country. Malaysian respondents cited concern that their treatment would stop working as the most frequent fear (32%). Italy was the country with the highest proportion of respondents worried about dying (45.5%). European and Latin American respondents were significantly more likely to fear dying than respondents from the United States or the Asia/Pacific region (P < .05). Female respondents were significantly more likely than male respondents to fear that they would become too sick to care for their children (P < .05).
Current Sex Practices
One third of respondents claimed a monogamous sexual relationship, and significantly more South African respondents than others claimed to practice monogamy (P < .05). After South African respondents (47.5% monogamous), the highest proportions classifying themselves as monogamous were in Brazil (41.9%), Malaysia (40%), and France (39%), and the lowest proportions in Korea (17.7%) and New Zealand (27.7%). (Data on current sex practices are available at www.iapac.org.) In the United States and Latin America, significantly more treated than untreated respondents reported being monogamous (P < .05).
United States respondents were significantly more likely than Latin American and Asia/Pacific respondents to say they abstain from sex altogether (P < .05). European respondents on treatment were significantly more likely than those who were untreated to abstain from sex (P < .05). Substantial minorities in many countries admitted having casual sex partners or to be in a long-term relationship but not monogamous, including 34.7% and 13.9% in New Zealand, 24.8% and 14.3% in the United States, 26.5% and 6% in Italy, and 13.1% and 13.8% in Korea. One quarter or more respondents in Italy (25%), Russia (28%), Brazil (28.1%), Korea (33.1%), and Argentina (38.2%) said they would prefer not to answer questions about their sexual relations.
Discussion
To our knowledge, this 2555-person cross-sectional survey is the largest sampling of opinions, beliefs, and behaviors of HIV-positive individuals and the only extensive multinational study of its kind. Analysis of responses to dozens of questions underlines the heterogeneity of HIV-positive individuals across 6 regions but also points out substantial similarities in how people from diverse regions weigh the impact of HIV disease and its treatment, as well as the promise of prolonged survival through ART. The survey also uncovered some findings that counter conventional wisdom about patient behaviors and beliefs, particularly in South Africa. Across North and South America, Europe, Asia, South Africa, and New Zealand, respondents expressed high degrees of satisfaction with ART and minimal to moderate concern that it impairs their quality of life ( Table 2 ). Satisfaction with antiretroviral drugs varied with how the question was asked. For example, the highest proportions of respondents complaining of poor medication tolerability lived in Italy and Russia, but Korea and Germany had the most respondents claiming ART had a negative impact on their quality of life (Table 2 ). Respondents' greatest hope for future antiretroviral drugs is that they will allow them to live longer lives. Yet a large majority of respondents (74.8%) already believes treatment for HIV and AIDS will help them live a long life, whereas only 6.6% disagreed completely or somewhat with that idea. Respondents on treatment were significantly more likely than those who were untreated to believe that treatment will help them live a long life.
Surveys of 925 Australians with HIV in 1997 and 924 in 1999 also documented favorable attitudes toward antiretroviral drugs, even though patients in the latter survey did not report improvements in physical well-being, employment levels, or financial circumstances. 6 The good self-reports of general physical health in ATLIS respondents could reflect the more potent, less toxic antiretroviral drugs used today than in the late 1990s. Although fears of getting too sick to care for oneself or dying predominated as concerns about HIV infection across all regions, relatively small minorities-never more than half-expressed those concerns.
Although almost three quarters of respondents were currently taking medications for HIV or AIDS, 20% had never been treated. Among respondents never treated for HIV or AIDS, 23.3% attributed lack of treatment to the belief that they are not in danger of getting ill or that treatment would not help them.
These beliefs may be interpreted in 2 ways: Either respondents do not understand the grave threat of HIV infection or they have a high CD4 cell count and are following the predominant professional advice (at the time of this survey) that treatment risks outweigh benefits for people in the earlier stages of HIV infection.
Large majorities of ATLIS respondents in Latin America, Asia, and South Africa stated their wish to know more about ART. Half or fewer respondents in two European, one Latin American, and one Asian country, as well as South Africa, correctly explained the meaning of undetectable HIV RNA (defined as <50 HIV RNA copies/mL of plasma), and 33.4% and 35.8%, respectively, of European and Latin American respondents did not know their CD4 cell count (Table 5) . Substantial minorities of all respondents also admitted not knowing what constitutes resistance to antiretroviral drugs. An earlier study of 200 Australians correlated a good understanding of resistance with better adherence to ART, 7 and the same correlation would probably hold true in ATLIS populations. Although most ATLIS respondents reported good overall adherence (Table 2 ) and a commitment to take medications regularly, widespread poor understanding of HIV disease and its treatment as reflected in the ATLIS results should encourage physicians and others to redouble their efforts to educate people living with HIV and AIDS.
Few respondents-even those currently taking antiretroviral drugs-claimed familiarity with current antiretroviral drug classes (Table 5) . These results may not reflect poor patient education or understanding as much as a greater focus on individual antiretroviral drugs a person is taking than on antiretroviral drug class groupings. However, these findings do reflect results of a 2004 cross-sectional survey involving 1667 HIV-infected patients in India, a country we did not survey. 8 Only 609 (36%) of the Indian survey respondents said they had heard of ART, and 19% believed antiretroviral drugs could cure HIV infection.
Concerns about antiretroviral drug side effects sometimes appear to reflect the makeup of patient populations in specific regions (Table 3 ). For example, the high proportion of Russian respondents "very" concerned about potential liver toxicity could reflect high proportions of injection drug use and hepatitis virus coinfection among Russians living with HIV and AIDS. Despite ongoing intense study of cardiovascular complications during ART, only 12.4% to 40.0% of respondents outside Latin America were "very" concerned about heart disease, although one third to one half in Latin America voiced this concern (Table 3 ). The higher proportion of US respondents worried about cardiovascular disease (34.4%) compared with Western Europeans (12.4% to 29.1%) may indicate more attention to this risk in sources available to patients, more intense cardiovascular disease monitoring by US clinicians, or generally higher cardiovascular disease rates in the United States than in some other countries.
South Africa is the only ATLIS country representing sub-Saharan Africa, which remains the epicenter of the global HIV epidemic. ATLIS uncovered several interesting findings in the 125 women and 75 men surveyed in South Africa, a distribution linking South Africa and the Caribbean region as geographical areas in which female respondents outnumbered male respondents. Three quarters identified themselves as heterosexual, and most were either single (36.5%) or single and in a long-term relationship (42%) ( Table 1) . Only 11% were married. This population had a mean age of 35.4 years, 57.5% had less than a high school education. Only 18.5% had full-time employment and 15.5% part-time employment.
Despite reports of ongoing HIV stigma and discrimination in South Africa, respondents from this country were significantly more likely than others to tell family members they had HIV infection. Perhaps even more surprising is the finding that South African respondents were significantly less concerned than counterparts elsewhere about others knowing their HIV status. South Africa has one of the best health care systems in sub-Saharan Africa, although it faces challenges uncommon in the United States and Western Europe. Yet only 13% of South African respondents reported poor overall health, perhaps because the mean CD4 count lay at 369 cells/mm 3 in this group, 72% of whom were being treated for HIV infection. Fewer than one quarter of South African respondents reported depression, a much lower rate than in Western Europe, the United States, or New Zealand.
Self-reported adherence to ART was as high in South Africa as in any country, and higher than in Korea, New Zealand, Mexico, Brazil, the United States, Russia, or any Western European country (Table 2 ). This result corroborates other studies of treatment adherence by South Africans. [9] [10] [11] South African respondents were significantly more likely than others to claim their medications did not negatively affect quality of life. And significantly fewer South African respondents than others were concerned about potential side effects.
ATLIS results in South Africa generally reflect some earlier findings in a cross-sectional survey of 105 HIV clinic patients in Soweto, South Africa, 12 even though only 30% of that population was taking antiretroviral drugs, compared with 71.5% in ATLIS. Whereas 90% in Soweto had disclosed their HIV status to others, only 62% told their current sex partner. Similarly, almost all ATLIS respondents had told their parents or siblings they had HIV infection, whereas only 29.3% told a spouse or significant other and 17.8% told another sex partner. Whereas 65% in the Soweto study agreed that missing antiretroviral drug doses can lead to disease progression, 74.8% of ATLIS respondents maintained they would take antiretroviral drugs over the long term to prevent health risks.
Sexual transmission remains the most frequent cause of new HIV infections worldwide. A recent Multicenter AIDS Cohort Study survey of US MSM correlated decreased concern about HIV infection with higher proportions of unprotected sex partners. 13 A 2007 review of 53 published studies found unprotected anal intercourse more common in MSM with HIV infection than in MSM without HIV infection, and the anal intercourse rate in HIVpositive MSM rose in recent years.
14 Studies of French MSM and heterosexuals 15 and US women 16 also associate ART with riskier sexual behavior, although a 420-man study of London MSM showed that treatment can make some people more responsible sex partners. 17 ATLIS confirmed the London MSM results among the European group surveyed, finding that European respondents being treated for HIV or AIDS were significantly more likely than untreated European respondents to abstain from sex altogether. However, ATLIS results suggest high rates of casual sex will persist because only one third of respondents reported being in a monogamous relationship, substantial proportions reported casual and/or nonmarital sex, and fewer claimed to abstain from sex. These findings indicate that HIV educators across the globe have much work to do in dissuading HIV-positive people from transmitting their virus sexually.
This study has several limitations. Respondents were not selected to represent the entire HIV-positive population of their country. Because recruitment relied partly on Internet-based methods, participants may represent more educated or wealthier segments of the population. There is no way to ensure that respondents did not understate or exaggerate the truth in response to certain questions, such as those about treatment adherence. Respondents were recruited by multiple means and interviewed by different techniques; both of these design considerations could lead to differences in responses and may limit the robustness of between-country comparisons. Rewording of questions to make them socially acceptable in each country may also have led to differing responses.
Although we recruited respondents from several countries in the Americas and Europe, South Africa is the only nation from the African continent, and Malaysia and Korea are the only Asian nations included in the analysis. We stopped enrollment in Malaysia, Korea, and New Zealand below a 200-person target because of slow enrollment. Although we compared response differences between men and women, patients on and off treatment, and patients from 6 different regions, we did not try to correlate responses with factors such as age, HIV transmission route, or marital/partner status.
Despite these limitations, we believe ATLIS is a critical first step toward understanding differences and similarities in HIV-positive people worldwide, and especially those taking antiretroviral drugs. We encourage discussion and analysis of these results and recommend further similar work aimed at improving the care of HIV-positive people everywhere. For example, cross-country comparisons of HIV-positive patient opinions could be conducted as part of several large and ongoing prospective cohort studies involving several countries in Europe and North America. Researchers should consider mounting similar prospective cohort studies in Africa, Asia, Latin America, and the Caribbean so that these questions, and many others, can be addressed there in coming years.
